ArticleFrontiers in pediatrics2026
Pediatric video capsule endoscopy: diagnostic yield, safety, and clinical impact in a tertiary center.
Article in Frontiers in pediatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Video capsule endoscopy (VCE) enables direct, radiation-free visualization of the small bowel mucosa and is endorsed by pediatric guidelines as a key tool in the evaluation of Crohn's disease (CD). Despite this, VCE remains underused in routine pediatric practice, and its real-world clinical impact is insufficiently characterized. We aimed to assess the diagnostic yield, safety, and management consequences of pediatric VCE in a tertiary center and to compare its findings with cross-sectional imaging and biomarkers. Methods: We conducted a retrospective, single-center study of VCE procedures in children younger than 18 years performed between 2018 and 2024. Demographic, clinical, imaging, and laboratory data were reviewed to characterize indications, safety, and clinical yield. Results: Seventy-six VCE examinations were performed in 60 children (mean age 14.8 years; 41% female). Endoscopic placement was required in 19 patients (25%). Dissolvable patency capsule testing to evaluate non-retention of the real VCE was performed in 22/80 (27.5%) planned VCEs, with four failures that abrogated further application of VCE. The main indication for VCE was suspected or established CD (57 VCEs in 45 children); other indications included polyposis syndromes, eosinophilic gastrointestinal disease, iron deficiency anemia, and gastrointestinal bleeding. In the CD subgroup, VCE supported a new diagnosis in 13 of 28 cases (46%) and prompted disease reclassification in 12 of 29 cases (41%). Small bowel inflammation was noted in 35 of 42 VCEs (83%) in new or known patients with CD [Lewis score (LS) > 135], with a median LS of 563. VCE findings led to the initiation or escalation of CD treatment in 22 of 42 patients (52%). One capsule retention occurred, revealing a previously unsuspected severe stricturing (B2) phenotype and leading to a planned, nonurgent intestinal resection. Among the 46 children who underwent both VCE and cross-sectional imaging, concordance between VCE and MRE/IUS was modest ( Conclusion: VCE is a safe and well-tolerated modality for evaluating pediatric small bowel disease, particularly CD, and frequently reveals clinically relevant inflammation missed by conventional imaging. These findings support its broader integration into pediatric practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.